a-f. PSP significantly decreased NP-specific IgM responses at days 4 and 21 compared to ACACIA. by Bhagwant Kaur Sekhon (847697)

120-kDa Notch1 transmembrane domain (N1™) is decreased in Pn−/− molar PDL. by Hideyuki Tanabe (243557)

miR-275 and miR-305 maternal loss-of-function mutants exhibited impaired flight capability, decreased hatching rate and survival rate. by Junfei Xie (3148638)

Tg2576 mice treated with OG showed markedly increased α-secretase cleavage of APP and significantly decreased levels of Aβ generation. by She-Qing Zhang (446556)

Ppk1 levels are not affected by decreasing dendrite arbor size but are reduced when dendrite length increases. by Josephine W. Mitchell (17364781)

Elevated IDO activity in HD mouse brains is decreased by <i>ex-vivo</i> iron chelation. by David W. Donley (3111198)

“…<p>Mouse pups were supplemented with carbonyl iron from postnatal days 10–17 and then were sacrificed at 14 weeks of age. <b>A.</b> Striatal IDO activity is increased in N171-82Q HD mice and significantly decreased by <i>ex vivo</i> iron (III) chelation (50 μM deferoxamine). …”

Down-regulation of NNMT expression decreased the plate efficiency and attenuated the capacity of colony formation in soft ager by Jun Zhang (48506)

Mean (±1SD) better of the two eyes’ monocular FMTs and binocular flicker thresholds across 13 subjects plotted for mesopic condition as a function of target size. by C. Vijay Reena Durai (14498259)

Subjects:

Mean (±1SD) better of the two eyes’ monocular FMTs and binocular flicker thresholds across 13 subjects plotted for photopic condition as a function of target size. by C. Vijay Reena Durai (14498259)

Subjects:

Former Abusers of Anabolic Androgenic Steroids Exhibit Decreased Testosterone Levels and Hypogonadal Symptoms Years after Cessation: A Case-Control Study by Jon Jarløv Rasmussen (2993427)

“…</p><p>Methods</p><p>This study had a cross-sectional case-control design and involved 37 current AAS abusers, 33 former AAS abusers (mean (95%CI) elapsed duration since AAS cessation: 2.5 (1.7; 3.7) years) and 30 healthy control participants. …”

KOR-agonist (U50'488) and MOR-agonist (DAMGO) decrease symptoms in OVA-allergic mice. by Swantje C. Duncker (154707)

Figure S1 - Docosahexaenoic Acid Decreases Pro-Inflammatory Mediators in an <i>In Vitro</i> Murine Adipocyte Macrophage Co-Culture Model by Anna A. De Boer (510740)

Cumulative distribution of EQ-5D-3L utilities decreasingly ordered before and after the onset of cutaneous leishmaniasis symptoms. by Janaína de Pina Carvalho (12152812)

Annual number of outpatient visits in recurrence and non-recurrence groups. by Yasuyuki Sotani (20114144)

“…<p>In the recurrence group, mean outpatient visits (± standard deviation) decreased from 13.6 ± 3.0 to 11.9 ± 5.0, 8.1 ± 3.9, and 7.8 ± 3.2 at 1, 2, and 3 years postoperatively, respectively (Kruskal-Wallis test, P < 0.001; Dunn’s test, **P < 0.01). …”

Annual treatment frequencies in all eyes. by Yasuyuki Sotani (20114144)

“…<p>The number of anti-VEGF treatments, STTA, MA-PC, PPV, and total treatments (mean ± SD) significantly decreased from 2.6 ± 1.6, 0.3 ± 0.8, 0.6 ± 0.8, 0.1 ± 0.3, and 3.7 ± 1.7 preoperatively to 0.8 ± 1.9, 0.0 ± 0.2, 0.3 ± 1.0, 0.0, and 1.2 ± 2.2; at year 2 to 0.7 ± 2.0, 0.1 ± 0.6, 0.0 ± 0.2, 0.0 ± 0.2, and 1.0 ± 2.1; and at year 3 to 0.9 ± 2.2, 0.0, 0.2 ± 1.0, 0.0 ± 0.2, and 1.1 ± 3.1 (Kruskal–Wallis test, P < 0.001; Dunn’s test, **P < 0.01). …”

Annual number of outpatient visits in all eyes. by Yasuyuki Sotani (20114144)

“…<p>Mean visit frequency (mean ± standard deviation) significantly decreased from 11.5 ± 4.3 preoperatively to 8.8 ± 4.1, 5.0 ± 3.4, and 4.4 ± 3.2 visits in the first, second, and third postoperative years, respectively (Kruskal–Wallis test, P < 0.001; Dunn’s test, **P < 0.01). …”

Annual treatment frequencies in recurrence and non-recurrence groups. by Yasuyuki Sotani (20114144)

“…Mean outpatient visits in the recurrence group decreased from 13.6 ± 3.0 to 11.9 ± 5.0, 8.1 ± 3.9, and 7.8 ± 3.2 at 1, 2, and 3 years postoperatively, respectively (Kruskal-Wallis test, p < 0.001). …”

Discovery of IHMT-MST1-58 as a Novel, Potent, and Selective MST1 Inhibitor for the Treatment of Type 1/2 Diabetes by Yun Wu (150224)

Subjects:

Discovery of IHMT-MST1-58 as a Novel, Potent, and Selective MST1 Inhibitor for the Treatment of Type 1/2 Diabetes by Yun Wu (150224)

Subjects:

Relative Aggrecan mRNA expression levels, as measured by qPCR, in lentiviral-transduced control cells and 5 AggKD cell lines confirm decreased Aggrecan expression in the AggKD cell... by Juanita K. Hodax (6848540)